Annovis Bio Inc. Secures Full Patent Coverage for Buntanetap: Key Questions Answered

What is the significance of Annovis Bio Inc. securing full patent coverage for buntanetap?

Securing full patent coverage means Annovis Bio Inc. now has comprehensive protection for both the original and new crystalline forms of buntanetap, including composition of matter, mechanism of action, and use in multiple indications, ensuring exclusivity through 2046.

What are the benefits of the new crystalline form of buntanetap?

The new crystalline form of buntanetap offers improved stability with bioequivalence confirmed in both animal and human studies, as presented at the 2025 Alzheimer’s Association International Conference.

How does this patent expansion affect Annovis Bio Inc.’s position in treating neurodegenerative diseases?

This patent expansion strengthens Annovis Bio Inc.’s position by securing its intellectual property around buntanetap, a treatment aimed at neurodegenerative diseases like Alzheimer’s (AD) and Parkinson’s (PD), enhancing its ability to develop and commercialize innovative therapies.

Where can I find more information about Annovis Bio Inc. and its developments?

For more information, visit Annovis Bio Inc.’s website at www.annovisbio.com or follow them on LinkedIn, YouTube, and X. The latest news and updates are also available in the company’s newsroom at https://ibn.fm/ANVS.

What is BioMedWire’s role in disseminating information about Annovis Bio Inc.?

BioMedWire is a specialized communications platform that focuses on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, helping to distribute news and updates about companies like Annovis Bio Inc. to a wide audience.

When does the patent protection for buntanetap expire?

The comprehensive patent portfolio for buntanetap, including the new crystalline form, is protected through 2046.

Who is involved in the development and patenting of buntanetap?

Annovis Bio Inc., a late-stage clinical company headquartered in Malvern, Pennsylvania, is involved in the development and patenting of buntanetap, focusing on treatments for neurodegenerative diseases such as AD and PD.